Wolf Theiss has provided legal support for the April 2017 groundbreaking for the new Boehringer Ingelheim production facility in Vienna and advised on the creation of related contracts.
Wolf Theiss reports that EUR 700 million has been budgeted for the project, which is expected to generate 500 new jobs. The new facility, scheduled to go into operation in 2021, will produce biopharmaceutical products by means of cell cultures.
Wolf Theiss Partner Karl Koller led the project, working with Partner Thomas Anderl.
